Bio-Thera Claims A World First With Chinese Tocilizumab Approval
Actemra/RoActemra Gets NMPA Nod; Offers Option For COVID-19 Treatment
Executive Summary
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
You may also be interested in...
Dr Reddy’s Sees Tocilizumab Clear Phase I
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
Bio-Thera Moves Ahead With Secukinumab And Mepolizumab
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”